Category: Stock Market

  • Top broker says the Chalice Mining share price can rise almost 200%

    Vanadium Resources share price person riding rocket indicating share price increase

    Vanadium Resources share price person riding rocket indicating share price increase

    The Chalice Mining Ltd (ASX: CHN) share price was a strong performer on Thursday.

    The mineral exploration company’s shares stormed almost 7% higher to end the day at $4.00.

    The catalyst for this was the release of positive drilling results from the Dampier target.

    Can the Chalice Mining share price keep rising?

    The good news for investors is that one leading broker believes the Chalice Mining share price can keep rising… and rising.

    According to a note out of Bell Potter, its analysts have retained their speculative buy rating and $11.10 price target on the company’s shares.

    Based on the current Chalice Mining share price, this implies potential upside of 178% over the next 12 months.

    What did the broker say?

    Bell Potter was very pleased with the drilling results from the Dampier target. It highlights that these results are similar to the enormous Gonneville deposit and paint a very positive picture of its Julimar project. The broker said:

    These results are a very exciting development for CHN and are the strongest indication yet of further mineralisation at Julimar and for potential repeats of the Gonneville deposit. The mineralisation style is almost identical to Gonneville and the drilling has provided additional information that has enabled CHN to prioritise multiple targets.

    The step-out (~10km) from the Gonneville deposit and the continuity of ~350m strike and over ~250m dip for the initial three holes is highly encouraging for the prospectivity of the entire Julimar Complex.

    All in all, the broker believes this update as a big positive and continues to see significant value in its shares. Bell Potter concludes:

    With this latest update, we see the likelihood of further positive catalysts emerging on exploration success. Our valuation remains unchanged at $11.10/sh and we retain our Speculative Buy recommendation.

    The post Top broker says the Chalice Mining share price can rise almost 200% appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Chalice Mining Ltd right now?

    Before you consider Chalice Mining Ltd, you’ll want to hear this.

    Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Chalice Mining Ltd wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

    See The 5 Stocks
    *Returns as of July 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/oiuFSym

  • Why analysts love this ASX share that lost investors 5.5% in FY22

    A businessman hugs his computer.A businessman hugs his computer.

    It’s extremely rare to see the analyst community unanimously favour a particular stock.

    Much like the retail investor population, each professional also has their own style, taste and strategy. So what looks attractive to one analyst may not fit the criteria for another.

    But if there’s anything close to a unanimously loved ASX share right now, it’s CSL Limited (ASX: CSL).

    According to CMC Markets, 12 out of 13 analysts currently rate the biotechnology stock as a buy. 

    Ten of those 12 go as far as recommending it as a strong buy.

    Fallen star could represent a bargain

    Over the 2022 financial year, the CSL share price lost 5.5%. It’s still a long way from its pre-COVID high.

    Perhaps this represents great value to the analysts, who have seen CSL make many people wealthy over the long term.

    The share price closed Thursday at $287.

    According to The Motley Fool’s James Mickelboro, the team at Citi reckons there’s massive upside, slapping on a price target of $330.

    “US CMS data indicates continued price increases in immunoglobulin products. This is consistent with our expectation, as donor fees continue to remain elevated,” Citi’s notes read.

    “With plasma collections now back to pre-pandemic levels, we expect the market to shift its focus to the strong underlying plasma product demand.”

    Reporting season could surprise

    The biggest influence on the CSL share price over the last financial year, aside from the ongoing COVID-19 pandemic, was the acquisition of European pharmaceutical company Vifor Pharma towards the end of last year.

    At the time experts were divided over whether the deal was a positive one for CSL.

    But now that the dust has settled, there doesn’t seem to be as much angst about the $17.2 billion takeover.

    With August reporting season coming up, Switzer Financial Group director Paul Rickard this week noted that healthcare companies like CSL tend to have a track record of “surprising on the upside”.

    “The lower Australian dollar is helping as well,” he told Switzer TV Investing.

    The post Why analysts love this ASX share that lost investors 5.5% in FY22 appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Csl Limited right now?

    Before you consider Csl Limited, you’ll want to hear this.

    Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Csl Limited wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

    See The 5 Stocks
    *Returns as of July 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor Tony Yoo has positions in CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/3RY61Wj

  • Why Goldman Sachs just upgraded Pro Medicus shares

    Two brokers analysing stocks.

    Two brokers analysing stocks.

    The Pro Medicus Limited (ASX: PME) share price will be on watch on Friday.

    This follows the release of a positive broker note out of Goldman Sachs this morning.

    What is Goldman Sachs saying about Pro Medicus’ shares?

    According to the note, the broker has taken its sell rating off the health imaging technology company’s shares.

    Goldman has upgraded Pro Medicus to a neutral rating with an improved price target of $42.60.

    And while this is still lower than the current Pro Medicus share price of $45.19, the broker spoke very positively about the company’s outlook and artificial intelligence (AI) opportunity.

    What did the broker say?

    Goldman Sachs highlights that over the last decade there has been a lot written about the various benefits and applications of AI in radiology. At long last, the broker believes that the technology is finally approaching a tipping point in adoption.

    This could be good news for Pro Medicus, as Goldman Sachs believes it is the company that could benefit most from this technology. And while it acknowledges that it is still early days, the broker sees a big opportunity for the company.

    Goldman explained:

    Although still early days, we believe PME is better positioned than most to commercialise AI, as integration with its established Visage 7 Viewer provides a strong differentiation to the competition. However, competition is likely to be intense, with multiple players vying for platform share, and hence any sustained success is very far from assured.

    Whilst revenue contribution is still subject to various uncertainties, PME is now generating revenue from its breast density AI algorithm, and hence we feel it is now necessary to at least attempt to recognise what could be a meaningful growth driver through the mid/long-term. Based on our current assumptions, AI could be +3-9% accretive to our revenue forecasts in FY24-26E.

    The post Why Goldman Sachs just upgraded Pro Medicus shares appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

    See The 5 Stocks
    *Returns as of July 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus Ltd. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/G2yJrF3

  • 4 ‘quality’ ASX shares to buy in scary times: expert

    A woman sits at her computer with her hands clutched her the bottom of her face as though she may be biting her fingermails with a worried expression in her eyes and frown lines visible.A woman sits at her computer with her hands clutched her the bottom of her face as though she may be biting her fingermails with a worried expression in her eyes and frown lines visible.

    Investing in ASX shares in 2022 has not been for the faint-hearted.

    Inflation and interest rate worries have paralysed the market for the whole year, while Russia’s war in Ukraine and surging energy prices have just poured petrol on the volatility fire.

    Now, as Australians and Americans face higher mortgage repayments, there are fears that economies will fall into recession — and that it’s a sacrifice central banks are willing to accept to stop high inflation becoming entrenched.

    Scary times.

    In such turbulence Switzer Financial Group director Paul Rickard suggests that buying into the “safer” reliable companies might be an idea.

    “[Buying] the stock that was $10 and is now 50 cents, hoping that’s going to rebound, that’s a high-risk strategy for me,” he told Switzer TV Investing.

    “I’d rather stick to a couple of quality companies. And there are a couple out there that I think are showing reasonable rounding-type behaviour and are trading okay.”

    The company to boom when the economy recovers

    Rickard’s first pick is investment bank Macquarie Group Ltd (ASX: MQG).

    He noted the stock has come up about 7% off its low in mid-June, which is impressive resilience considering the rest of the ASX has plunged in that time.

    “The other reason why I like Macquarie is you know it’s got a great underlying business. You know that there are some pretty smart operators in Macquarie.”

    According to Rickard, the firm has a “good mix” of market-exposed investments and its fast-growing retail banking business.

    Like most investment banks, Macquarie does have some downside if the economy plunges into a recession or even a severe slowdown.

    But beyond that there is plenty of upside.

    “If the economy recovers and activity picks up… I’d say Macquarie’s a big beneficiary.”

    A reliable trio from a growing sector

    Healthcare is a sector that Rickard favours at the moment.

    He noted that in the US healthcare is often seen as a defensive sector, while Australia’s product-focused companies give the industry a growth flavour.

    And certainly with the current market sentiment so hostile towards technology, Rickard feels like growth shares in health could benefit.

    “Companies like CSL Limited (ASX: CSL), Resmed CDI (ASX: RMD) and Cochlear Limited (ASX: COH)… I think there’s good value there,” he said.

    “Again, they’re all stocks that aren’t going down and, if anything, companies like Resmed and Cochlear have been creeping up, as has CSL.”

    With reporting season coming up next month, Rickard said that these companies have a history of “surprising on the upside”.

    “The lower Australian dollar is helping as well.”

    The post 4 ‘quality’ ASX shares to buy in scary times: expert appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

    See The 5 Stocks
    *Returns as of July 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor Tony Yoo has positions in CSL Ltd., Cochlear Ltd., Macquarie Group Limited, and ResMed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd., Cochlear Ltd., and ResMed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool Australia has recommended Cochlear Ltd. and Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/leqEfWn

  • Here are 3 excellent ASX growth shares for investors to buy in July

    a man with a wide, eager smile on his face holds up three fingers.

    a man with a wide, eager smile on his face holds up three fingers.

    Are you wanting to add some ASX growth shares to your portfolio in July? If you are, you may want to look at the ones listed below.

    Here’s what you need to know about these growth shares:

    Aristocrat Leisure Limited (ASX: ALL)

    The first ASX growth share to look at is Aristocrat Leisure. It is one of the world’s leading gaming technology companies with a portfolio of poker machines and a lucrative digital business. The latter is generating significant recurring revenues from highly popular games such as RAID. And while the company recently missed out on the major acquisition of real money gaming (RMG) company Playtech, management stated that this won’t stop it from entering the potentially lucrative RMG market.

    Earlier this week the team at Citi put a buy rating and $41.00 price target on its shares.

    Breville Group Ltd (ASX: BRG)

    Another ASX growth share that could be a top option for growth investors is Breville. It is the leading appliance manufacturer behind the Baratza, Kambrook, Lelit, Sage, and Breville brands. Thanks to a combination of acquisitions, geographic expansion, and its investment in research and development, Breville has been growing at a solid rate for many years. Pleasingly, the company has been tipped to continue its growth in the years to come by a number of brokers.

    Morgans is one of those brokers and has an add rating and $32.00 price target on its shares.

    Lovisa Holdings Limited (ASX: LOV)

    A final ASX growth share that could be in the buy zone this month is Lovisa. It is a fast-fashion jewellery retailer with a store network that is growing rapidly. It could be a top long term option due to its global expansion plans, new and ambitious leadership team, and the popularity of its offering.

    Analysts at Morgans are very bullish and believe “now is the time LOV steps up to become a global force.” Its analysts have an add rating and $24.00 price target on its shares.

    The post Here are 3 excellent ASX growth shares for investors to buy in July appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

    See The 5 Stocks
    *Returns as of July 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Lovisa Holdings Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/LbKhRT9

  • The biggest risk and top opportunity for fixed income investors in 2022 revealed: fund managers

    A young woman sits with her hand to her chin staring off to the side thinking about fixed income opportunities in 2022 at her computer with a pen in her other hand and a cup of coffee beside. her in a home office environment.A young woman sits with her hand to her chin staring off to the side thinking about fixed income opportunities in 2022 at her computer with a pen in her other hand and a cup of coffee beside. her in a home office environment.

    Ask a Fund Manager

    The Motley Fool chats with fund managers so that you can get an insight into how the professionals think. In part three of this edition, we’re rejoined by Yarra Capital Management’s fixed income specialists, Darren Langer, co-head of Australian fixed income, and Chris Rands, co-portfolio manager of the Yarra Australian Bond Fund. Today they discuss the threats and opportunities for bond investors in the year ahead.

    The Motley Fool: We previously covered what a tough year it’s been in the bond markets amid the aggressive interest rate hike signals from the US Fed and the RBA. Do you have any investment regrets over the past year?

    Chris Rands: The biggest regret I have is that we bought the rising rates too early. If you think about that spread to cash I mentioned earlier, we didn’t think the market would be pricing in a 4% cash rate by the end of this year. That seemed way too high for us. Once the market was pricing in a cash rate of 3%, we thought that was a good time to buy, and it turned out that was too early because the market doesn’t think 3% is high enough anymore.

    I still think the market is overpriced and that it’s going to eventually come back.

    Darren Langer: We’re quite cynical about how central banks operate. Early on in the pandemic, we were talking about the fact that we don’t trust central banks to tell you what they’re really going to do. They tell you what they want you to hear. We thought they’d take a much slower path out of this. The sensible route is to go slower and not crush your economy on the way.

    MF: So why are we seeing this hawkish tightening from the Fed and RBA?

    DL: That last hit to energy prices with the Ukraine crisis has panicked central banks. And I think we underestimated just how much they would revert back to the 1990s thinking of having to kill inflation really quickly rather than looking at the underlying nature of what’s going on.

    Perhaps we weren’t cynical enough and should have gone with our gut feeling that central banks would overreact to the situation rather than take a more nuanced view.

    MF: Despite the difficult environment, what were some of your winning investment decisions?

    CR: Coming into this year we didn’t have much of a credit position. When spreads got really tight last year, we took the opportunity to sell the majority of our credit. What’s been happening this year, as rates have sold off and central banks began to take excess liquidity out of the market, credit spreads have actually been widening. Corporate bonds have been having a relatively tough time.

    So, we did well timing that credit spread. Hopefully, the next leg of this positive trade will be buying the attractive spread back at some stage.

    MF: Has Russia’s invasion of Ukraine changed your investment approach?

    CR: It doesn’t change any of our investment processes, but it does change how we think about inflation and those types of things. The way this turns up in investment strategies is [to] assess what impact we believe this conflict will have on inflation and, therefore, causes the RBA’s reaction.

    If we have a prolonged conflict, what does that do to oil prices and where does that put inflation? And, alternatively, if the conflict were to end, where does that put oil and what does that mean for the RBA’s response?

    This isn’t something we’ve had to really worry about for the past 10 or so years. There are always minor geopolitical conflicts popping up, but not one of this magnitude and with such a large flow-on effect via the energy markets.

    DL: One thing that’s surprised us a little is we would have thought, in a world where there is conflict, Australia is a relatively safe haven for investors. We have a relatively stable economy and we’re a long way from everybody else geographically.

    But what we’ve actually seen is that Australian bonds as a spread to US bonds have been widening over the last six to 12 months. So, we’ve actually underperformed the US, in particular. That’s been a surprise because we expect our rates to be a little lower than the US. We have a highly rated market relative to other countries. But there hasn’t been the same demand for Australian bonds from international investors that we might have expected.

    It doesn’t affect us directly, because we only invest in the domestic market.

    MF: What’s the biggest threat for fixed-income investors in the year ahead?

    CR: That the central banks continue on this hawkish path and march rates up to what the market is currently forecasting. If the RBA is able to get the cash rate to 4% over the next six to nine months, I don’t think that’s going to be a very good environment for other risk assets. And that’s when you’ll start to question whether the corporates can handle the slowdown in growth that’s coming.

    DL: If you think about the main risks in fixed income, higher interest rates are one, and credit risk is the other main one. For people investing in fixed-rate funds, higher rates are going to cause problems to returns.

    There are floating rate funds in the market, but a lot of the floating rate funds also take credit risk. So if we keep pushing rates higher, the chances of recession become higher and that becomes a risk on the credit side.

    MF: And what’s the biggest opportunity in the fixed income space?

    CR: I think the biggest opportunity is that central banks pull up earlier than the market expects. If the RBA were to stop at 2% to 2.5%, then fixed rates are too high. So there’d be a relief rally simply because you don’t get to the levels that the market is forecasting relative to what the RBA actually does.

    So the biggest opportunity is that we get a small slowdown in growth that causes central banks to re-evaluate what they’re doing and pause the hikes. If it’s a fast slowdown in growth, then it’s a ‘who knows what’s going to happen’ environment again.

    DL: If we end up with a lower rate profile, fixed-rate funds will do quite well from their interest rate exposure. But also the credit spreads have widened quite a bit, so there have been lots of opportunities to invest in good quality corporates at reasonable spreads.

    If we end up having a soft landing, the corporate market should do quite well.

    **

    If you missed the earlier installations of our interview with Yarra Capital’s Darren Langer and Chris Rands, you can find part one here and part two here.

    (You can find out more about the Yarra Australian Bond Fund here.)

    The post The biggest risk and top opportunity for fixed income investors in 2022 revealed: fund managers appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

    See The 5 Stocks
    *Returns as of July 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/XfTUaeS

  • Here are 2 ASX 200 dividend shares analysts rate as buys

    Australian dollar notes rolled into bundles.

    Australian dollar notes rolled into bundles.

    Looking for dividend shares to buy this month? Then the two listed below that have been given buy ratings could be worth considering.

    Here’s what you need to know about these ASX 200 dividend shares:

    Australia and New Zealand Banking Group (ASX: ANZ)

    The first ASX 200 dividend share to look at is ANZ. It is of course one of Australia’s big four banks.

    ANZ could be a top option for income investors that don’t already have exposure to the banking sector. Particularly given its solid performance so far in FY 2022 and recent share price weakness.

    In respect to the former, during the first half, ANZ reported cash earnings from continuing operations of $3,113 million. This was a 4% increase over the prior corresponding period.

    As for the former, the ANZ share price has lost 19% of its value since the start of the year. This means that the potential yields on offer with its shares have now widened materially. For example, Citi is forecasting fully franked dividends per share of 147 cents in FY 2022 and then 170 cents in FY 2023.

    Based on the current ANZ share price of $22.80, this implies yields of 6.45% and 7.45%, respectively.

    Citi also sees plenty of value in its shares and has put a buy rating and $30.75 price target on them.

    Harvey Norman Holdings Limited (ASX: HVN)

    Another ASX 200 dividend share to consider is retail giant Harvey Norman. It could be in the buy zone according to analysts at Goldman Sachs.

    The broker remains positive on the retailer despite the tough operating environment. It prefers Harvey Norman due to its valuation and it having “more protection from online competition given higher regional and boomer exposure.”

    Goldman Sachs is forecasting fully franked dividends per share of 42 cents in FY 2022 and 39 cents in FY 2023. Based on the current Harvey Norman share price of $3.89, this will mean yields of 10.8% and 10%, respectively.

    The broker has a buy rating and $5.80 price target on its shares.

    The post Here are 2 ASX 200 dividend shares analysts rate as buys appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

    See The 5 Stocks
    *Returns as of July 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Harvey Norman Holdings Ltd. The Motley Fool Australia has positions in and has recommended Harvey Norman Holdings Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/OY8HjnA

  • I’m sticking by this ‘quality’ ASX share that’s fallen 20%: expert

    a man sits at his computer screen scrolling with his fingers with a satisfied smile on his face as though he is very content with the news he is receiving.a man sits at his computer screen scrolling with his fingers with a satisfied smile on his face as though he is very content with the news he is receiving.

    One ASX stock is selling at a discount right now, even though it represents a quality business poised for “superior earnings growth” in the medium term.

    That’s the view of Wilsons head of investment strategy David Cassidy, who said Macquarie Group Ltd (ASX: MQG) is a “quality cyclical”. 

    “Quality cyclicals do not have the same persistent growth characteristics as pure structural growth stocks,” he said in a Wilsons memo.

    “However, quality cyclicals usually have a structural growth story embedded within the company.”

    Immediate growth might be hampered for Macquarie as the economy slows down, but in the longer term “the structural growth drivers should outweigh the cyclicality”.

    How did Macquarie perform in the 2022 financial year?

    In a period that’s seen plenty of bruising among ASX shares, Macquarie fared respectably, gaining 5% for the 2022 financial year.

    At its peak in November 2021, it even became one of the big four banks.

    This is all while giving out a handy dividend yield of 3.66%.

    While it has made its name over the decades as an investment bank, its small retail arm is fast gaining traction in the competitive Australian market.

    Its home loan book has been growing rapidly over the last three years. 

    “We have been impressed by the growth rate of Macquarie’s lending business,” said Cassidy.

    “If it continues to grow at its current pace, it is very possible that the banking segment could capture over 10% of Australia’s household lending by the end of the decade.”

    To grow the deposit side of the retail market, last month Macquarie even started offering transaction accounts that pay out a no-questions-asked 1.5% per annum interest rate.

    This year’s plunge just makes it a bargain

    Like many ASX shares, Macquarie investors have been forced to take a haircut in 2022.

    For the year-to-date, the stock price is down almost 20%.

    But Cassidy reckons that this merely presents a “good opportunity to buy a quality cyclical at a reasonable price”.

    The bank’s early investment in industries that drive decarbonisation gives it excellent upside, he feels.

    “Macquarie and Brookfield… have the first mover advantage in green energy,” said Cassidy.

    “Macquarie is well-positioned to take advantage of this opportunity and is one of the few ASX stocks exposed to this macrotrend.”

    And despite the share price doubling over the past five years, this year’s sell-off now has the stock on undemanding ratios.

    “Macquarie currently trades on a PE multiple of 15x (1-year forward earnings) — lower than it has been trading on post 2020 and close to its 5-year historical average,” said Cassidy.

    “We think this valuation looks reasonable due to the strong long-term earnings growth potential for Macquarie and unique leverage to the energy transition.”

    The post I’m sticking by this ‘quality’ ASX share that’s fallen 20%: expert appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Macquarie Group Ltd right now?

    Before you consider Macquarie Group Ltd, you’ll want to hear this.

    Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Macquarie Group Ltd wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

    See The 5 Stocks
    *Returns as of July 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor Tony Yoo has positions in Macquarie Group Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/uXLIxDK

  • 5 things to watch on the ASX 200 on Friday

    A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements

    A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements

    On Thursday, the S&P/ASX 200 Index (ASX: XJO) was back on form and charged higher. The benchmark index rose 0.8% to 6,648 points.

    Will the market be able to build on this on Friday and end the week on a high? Here are five things to watch:

    ASX 200 expected to rise again

    The Australian share market looks set to end the week on a positive note following a strong night of trade on Wall Street.  According to the latest SPI futures, the ASX 200 is expected to open 52 points or 0.8% higher this morning. In the United States, the Dow Jones rose 1.1%, the S&P 500 climbed 1.5%, and the Nasdaq stormed 2.3% higher.

    Oil prices rebound

    Energy producers including Beach Energy Ltd (ASX: BPT) and Woodside Energy Group Ltd (ASX: WDS) could have a good finish to the week after oil prices rebounded. According to Bloomberg, the WTI crude oil price is up 3.7% to US$102.24 a barrel and the Brent crude oil price is up 3.4% to US$104.13 a barrel. Supply concerns offset recession fears and drove prices higher.

    Chalice rated as a buy

    The Chalice Mining Ltd (ASX: CHN) share price could be great value according to analysts at Bell Potter. According to a note, the broker has retained its speculative buy rating and $11.10 price target on the mineral exploration company’s shares. Bell Potter believes recent drilling results at the Dampier target are exciting. It said: “These results are a very exciting development for CHN and are the strongest indication yet of further mineralisation at Julimar and for potential repeats of the Gonneville deposit.”

    Gold price edges higher

    Gold miners Newcrest Mining Ltd (ASX: NCM) and St Barbara Ltd (ASX: SBM) will be on watch after the gold price edged higher overnight. According to CNBC, the spot gold price is up 0.15% to US$1,739.10 an ounce. The gold price was boosted by a softer US dollar.

    Pro Medicus shares upgraded

    The Pro Medicus Limited (ASX: PME) share price is now around fair value according to analysts at Goldman Sachs. The has upgraded its shares to neutral from sell with a $42.90 price target. Goldman is bullish on its AI opportunity in radiology. It said: “Although still early days, we believe PME is better positioned than most to commercialise AI, as integration with its established Visage 7 Viewer provides a strong differentiation to the competition.”

    The post 5 things to watch on the ASX 200 on Friday appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

    See The 5 Stocks
    *Returns as of July 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus Ltd. The Motley Fool Australia has positions in and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/GzEJ7U3

  • Analysts name 2 ASX 200 blue chip shares to buy

    A man with a yellow background makes an annoncement, indicating share price changes on the ASX

    A man with a yellow background makes an annoncement, indicating share price changes on the ASX

    If you’re wanting to build a strong portfolio, owning a few blue chips could be a good starting point.

    Blue chips are generally large companies that have been operating for many years, have stable cash flows, and experienced management teams. This tends to make them lower risk options and a good foundation to build a portfolio from.

    But which blue chip shares should you consider buying? Two that analysts rate highly are listed below:

    CSL Limited (ASX: CSL)

    The first blue chip ASX 200 share to look at is leading biotechnology company CSL.

    It is the name behind the CSL Behring plasma therapies business and the Seqirus vaccine business. In addition, the company is in the process of acquiring Vifor Pharma for $16.4 billion.

    Vifor Pharma has a focus on iron deficiency, nephrology, and cardio-renal therapies. It also has a research and development (R&D) pipeline that complements CSL’s existing R&D activities and should be supportive of long term growth.

    Citi is bullish on the company and has a buy rating and $330.00 price target on its shares. It said:

    With plasma collections now back to pre-pandemic levels, we expect the market to shift its focus to the strong underlying plasma product demand. This should lead to strength in the CSL share price.

    Wesfarmers Ltd (ASX: WES)

    Another ASX 200 blue chip share that could be a top option for investors is Wesfarmers.

    It is the company behind retail brands such as Bunnings, Kmart, and Priceline Pharmacy, and a collection of chemicals businesses. Combined with its strong management team and equally strong balance sheet, which provides further M&A opportunities, the future looks bright for Wesfarmers.

    Morgans certainly believes that to be the case. So much so, it has add rating with a price target of $58.40. It commented:

    We continue to see WES as a long-term, core portfolio holding with a strong mix of businesses, highly regarded management team and a healthy balance sheet.

    The post Analysts name 2 ASX 200 blue chip shares to buy appeared first on The Motley Fool Australia.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

    See The 5 Stocks
    *Returns as of July 7 2022

    (function() {
    function setButtonColorDefaults(param, property, defaultValue) {
    if( !param || !param.includes(‘#’)) {
    var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
    button.style[property] = defaultValue;
    }
    }

    setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
    setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
    setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
    })()

    More reading

    Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has positions in and has recommended Wesfarmers Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    from The Motley Fool Australia https://ift.tt/YskL7uS